Results 11 to 20 of about 7,390 (165)

Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review [PDF]

Фармакоэкономика, 2018
Aim: To analyze the efficacy, safety and pharmacoeconomic aspects of using ocrelizumab in adult patients with relapsing/remitting multiple sclerosis (R/R MS).Materials and Methods.
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin   +6 more
doaj   +2 more sources

Ocrelizumab in treatment of primary-progressive multiple sclerosis: systematic review [PDF]

Качественная клиническая практика, 2018
Aim. To analyze the efficacy, safety and pharmacoeconomic indicators of ocrelizumab in adult patients with primary progressive multiple sclerosis (PPMS). Methods.
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, E. M. Olyushina, K. I. Polyakova, A. G. Fisun, M. G. Grinin, K. A. Kokushkin   +8 more
doaj   +2 more sources

Ocrelizumab as a breakthrogh in multiple sclerosis treatment [PDF]

Journal of Education, Health and Sport, 2021
Multiple sclerosis is the most commonly occurring inflammatory disease of the nervous system. It is estimated that over 2 million people suffer from this disease.
Marcin Zaniuk, Marta Kozłowska, Adrianna Gorecka, Magdalena Zawiślak, Patryk Zimnicki   +4 more
doaj   +2 more sources

Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study

Annals of Clinical and Translational Neurology
Objective Subcutaneous ocrelizumab is being developed to provide treatment flexibility and additional choice to patients with multiple sclerosis. OCARINA I (NCT03972306) is an open‐label, multicenter, Phase 1b, dose‐finding study to investigate the ...
Scott D. Newsome, Lawrence Goldstick, Derrick S. Robertson, James D. Bowen, Robert T. Naismith, Ben Townsend, Catarina Figueiredo, Heidemarie Kletzl, Mylene Giraudon, Oscar Bortolami, Dusanka Zecevic, Caroline Giacobino, Susanne Clinch, Yun‐An Shen, Gurpreet Deol-Bhullar, Robert A. Bermel   +15 more
doaj   +2 more sources

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients

Cells, 2018
Ocrelizumab, a humanized monoclonal anti-CD20 antibody, has shown pronounced effects in reduction of disease activity in multiple sclerosis (MS) patients and has recently been approved for the treatment of patients with relapsing MS (RMS) and primary ...
Stefan Gingele, Thais Langer Jacobus, Franz Felix Konen, Martin W. Hümmert, Kurt-Wolfram Sühs, Philipp Schwenkenbecher, Jonas Ahlbrecht, Nora Möhn, Lars H. Müschen, Lena Bönig, Sascha Alvermann, Reinhold E. Schmidt, Martin Stangel, Roland Jacobs, Thomas Skripuletz   +14 more
doaj   +2 more sources

Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis

, 2023
IMPORTANCE Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, a
Zwanikken, Cees, Rasmussen, Peter Vestergaard, Eichau, Sara, Kuhle, Jens, Sanchez-Menoyo, Jose L., Fragoso, Yara, Yamout, Bassem, Taylor, Lisa, Sharmin, Sifat, Salvatore, Lo Fermo, Chisari, Clara, Al-Harbi, Talal, Shaygannejad, Vahid, Khoury, Samia J., Gray, Orla, Butzkueven, Helmut, Prat, Alexandre, Laureys, Guy, Turkoglu, Recai, McCombe, Pamela, Massey, Jennifer, MacDonell, Richard, Jensen, Ana Voldsgaard, Stilund, Morten Leif Munding, Saiz, Albert, Larochelle, Catherine, Alroughani, Raed, Barzinji, Ismael, Weglewski, Arkadiusz, Lalive, Patrice, Terzi, Murat, MSBase Study GroupDanish MS Registry Study Group, [missing], Nielsen, Helle Hvilsted, Slee, Mark, Svendsen, Kristina Bacher, Willekens, Barbara, Diamanti, Matteo, Den braber-Moerland, Leontien, Barnett, Michael, Van Hijfte, Liesbeth, Cabrera-Gomez, Jose Antonio, Nguyen, Ai-Lan, Amato, Maria Pia, Horakova, Dana, Decoo, Danny, Oh, Jiwon, Al-Asmi, Abdullah, Issa, Nadia Mubder, Skibina, Olga, Hughes, Stella, Ozakbas, Serkan, Taylor, Bruce, Roullet, Etienne, Cartechini, Elisabetta, John, Nevin, Sejbæk, Tobias, Garber, Justin, Izquierdo, Guillermo, Van Pesch, Vincent, Ampapa, Radek, Karabudak, Rana, Lechner-Scott, Jeannette, Havrdova, Eva, Boz, Cavit, Spitaleri, Daniele, Patti, Francesco, Dwyer, Chris, Girard, Marc, Soysal, Aysun, Prakash, Sivagini, McDonnell, Gavin, King, John, Besora, Sarah, Baker, Josephine, Kant, Matthias, Magyari, Melinda, Blanco, Yolanda, Hodgkinson, Suzanne, Malpas, Charles B., Buzzard, Katherine, Prevost, Julie, Roos, Izanne, Grammond, Pierre, Sellebjerg, Finn, Kilpatrick, Trevor, Monif, Mastura, Grand’Maison, Francois, Kalincik, Tomas, Jose Sa, Maria, Gobbi, Claudio, Ramo-Tello, Cristina, van der Walt, Anneke, D'Amico, Emanuele   +92 more
core   +3 more sources

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.

, 2023
IMPORTANCE: Natalizumab cessation is associated with a risk of rebound disease activity. It is important to identify the optimal switch disease-modifying therapy strategy after natalizumab to limit the risk of severe relapses.
Butler, Ernest, Eichau, Sara, Kuhle, Jens, Yamout, Bassem, Khoury, Samia J., Khoury, Samia J, Butzkueven, Helmut, Macdonell, Richard A. L., Prat, Alexandre, MSBase Study Grp, MSBase Study Grp, Laureys, Guy, Grand'Maison, Francois, MSBase Study Group, [missing], Alroughani, Raed, Terzi, Murat, Slee, Mark, Barnett, Michael, Van Hijfte, Liesbeth, Sa, Maria Jose, Zhu, Chao, Gerlach, Oliver, Horakova, Dana, Macdonell, Richard A L, Skibina, Olga, Ozakbas, Serkan, Izquierdo, Guillermo, Garber, Justin, Van Pesch, Vincent, Van Wijmeersch, Bart, Lechner-Scott, Jeannette, Boz, Cavit, Patti, Francesco, Weinstock-Guttman, Bianca, Girard, Marc, Kermode, Allan G, Duquette, Pierre, Zhou, Zhen, Hodgkinson, Suzanne, Buzzard, Katherine, Prevost, Julie, Jokubaitis, Vilija, MSBase Study Group, Grammond, Pierre, Monif, Mastura, Kalincik, Tomas, Grand’Maison, Francois, Kermode, Allan G., Merlo, Daniel, van der Walt, Anneke   +48 more
core   +2 more sources

Alopecia universalis in a patient under treatment of Ocrelizumab after switching from Rituximab (PP-06) [PDF]

Neurology Letters, 2023
Background: Ocrelizumab is a humanized monoclonal antibody, which acts as anti-CD20 antibody. It is used as a treatment of both relapsing-remitting MS and Progressive type.
Mahshid Mahyad, Mohammad Ali Nahayati, Mahboubeh Ebrahimian   +2 more
doaj  

Comparative effectiveness of natalizumab ocrelizumab in multiple sclerosis: a real-world propensity score–matched study

Therapeutic Advances in Neurological Disorders, 2022
Background: For treatment of relapsing-remitting multiple sclerosis (RRMS), a broad range of disease-modifying therapies (DMT) is available. However, few comparative effectiveness studies between different drugs have been performed.
Katrin Pape, Leoni Rolfes, Falk Steffen, Muthuraman Muthuraman, Melanie Korsen, Sven G. Meuth, Frauke Zipp, Stefan Bittner   +7 more
doaj   +1 more source

Breast Carcinoma After Ocrelizumab Therapy in Multiple Sclerosis Patients: A Case Series and Literature Review

Journal of Central Nervous System Disease, 2021
Ocrelizumab is a humanized CD20 monoclonal antibody which was approved for management of Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS) in 2017.
Andrew Kelsey MD, Gabriella Casinelli MD, Medha Tandon MD, Shitiz Sriwastava MD   +3 more
doaj   +1 more source